12:00 AM
Nov 03, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

HA-Irinotecan: Phase III data

The double-blind, Australian Phase III ACO002 trial in 415 irinotecan-naive patients who failed previous therapy showed that HA-Irinotecan as part of FOLFIRI therapy as second- or third-line treatment missed the primary endpoint of improving median PFS vs. FOLFIRI therapy with standard irinotecan (5.5 months for both arms). A planned...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >